ESR1 and breast cancer: This is consistent with the reasoning that if hormone-dependent breast cancers respond to estradiol challenge with an increase in FDG uptake [16-18], then tumors dependent upon the ER pathway for growth should display a decline in FDG uptake as AI therapy lowers estradiol levels.